A practical reference on WADA prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-26 and is reviewed periodically as new material appears.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Sandler (10 January 1927 – 6 October 1998), South African Jewish British psychoanalyst within the Anna Freud Grouping – now the Contemporary Freudians – of the British Psychoanalytical Society; perhaps best known for what has been called his 'silent revolution' in re-aligning the concepts of the object relations school within the framework of ego psychology; editor of the International Journal of Psycho-Analysis and President of the International Psychoanalytical Association; was the first Sigmund Freud Professor of Psychoanalysis at the Hebrew University of Jerusalem. Philippe Sands, KC (born 17 October 1960), writer, journalist and lawyer 11 King's Bench Walk; Director of the Centre on International Courts and Tribunals; counsel and advocate before many international courts and tribunals, including the International Court of Justice, the International Tribunal for the Law of the Sea, the European Court of Justice, the European Court of Human Rights and International Criminal Court;serves on panel of International Centre for the Settlement of Investment Disputes (CAS).; is author of seventeen books on international law as well as writing a number of geo-political texts; served as President of English PEN; appointed Professor of Law at Harvard Law School; co-founder of the Centre for International Environmental Law; and the Project on International Courts and Tribunals (1997); served as a Commissioner on the UK Government Commission on a Bill of Human Rights. Donald Sassoon (b.
Acting as a pro-apoptotic protein in many contexts, the normal levels of this protein mean that, in most cases, the initiated cell-death signaling pathways have an influence on the mitochondrial apoptosis pathway. This protein can have a premature prolonged apoptotic response with the risk of having not enough galectin-7 to re-epithelialize, delaying wound repair and skin closure through skin cell migration. This can be seen in aged skin which is considered to be a potential reason why wound repair is delayed in older individuals who would have less of this protein in them. With varying roles depending on the cellular conditions and factors, the protein is researched under induced ectopic expression in cancerous conditions. The discovered association between apoptosis and an over expression of galectin-7 has been found in apoptotic keratinocytes. The possible issue of the process of re-epithelialization being compromised or delayed would result in painful and serious wound disorders that would be difficult to treat as it has already affected the human tissue. The dangers of failure of re-epithelialization causes concern for uncontrolled inflammation, especially in the intestinal tract, and other immune responses that are more general. The cause for this isn't so much the inability for cell proliferation but instead the potential for the epithelium to migrate across the bed of the wound decreasing.
Regional treatment centres had also been set up, with large increases in the number of infected in the South Pyongan and South Hamgyong provinces. On 20 May, 168 confirmed cases of COVID-19 were reported, with cases of reported fever nearing 2 million, according to NK News. On 3 June, NK News reported that GAVI had received information that North Korea had started its vaccination rollout with Chinese vaccines, with an anonymous source telling Radio Free Asia that the first doses were being administered to soldiers working in the construction sector. From around June, vehicles had started reappearing in satellite imagery in Pyongyang, which suggested that the lockdown was at least being partially lifted in Pyongyang, with a source alleging that restrictions were relaxed to allow for a few hours of outdoor time every day from late May, though provincial cities appeared to be still locked down.
Sources: en.wikipedia.org
Insufficient recognition has been given to Paulescu, the distinguished Romanian scientist, who at the time when the Toronto team were commencing their research had already succeeded in extracting the antidiabetic hormone of the pancreas and proving its efficacy in reducing the hyperglycaemia in diabetic dogs.
Heroin is produced from opium, which is regulated differently around the world. Unlike coca leaves in Peru—handled exclusively by the state monopoly, the National Coca Company (ENACO)—there is no state company dedicated to the commercialization of opium and its derivatives. While international treaties—such as the Single Convention on Narcotic Drugs (1961)—require strict state control or monopoly over the legal production and commercialization of opium for medical and scientific purposes, in practice, only a few countries maintain such a state monopoly today. Notably, India operates a state monopoly through the Government Opium and Alkaloid Factories (GOAF), also known as Opium and Alkaloid Works, which is responsible for processing raw opium into alkaloids for the pharmaceutical industry and managing the legal opium trade for medical and scientific use. Legal opium production in India, as well as in countries such as Turkey, Australia, France, Japan, and the UK, supplies licensed pharmaceutical manufacturers under close supervision to prevent diversion to illicit markets.
== Interpretation and application == Monazite geochronology can reveal complex geological history recorded in the monazite mineral grains. The characteristic composition and age of each domain or zone represent a past geological event with a certain age. The key challenge in monazite geochronology is to correctly relate textures and compositions in each domain to the associated geological events which formed them. Even a single monazite grain may reveal a complex history, in which geologic events maybe inter-related or coeval, making discrimination difficult. The section below aims to briefly explain how composition and age data are interpreted to link different types of events.
Sources: en.wikipedia.org
=== Immune dysregulation === MS usually begins when immune cells known as T cells and B cells erroneously attack the body's own nervous system by releasing signals that cause inflammation in brain and other neurological tissues. This is supported by the presence of certain antibodies (oligoclonal IgG bands) commonly found in the spinal fluid of people with MS. Although T cells have been considered to be the major contributors to the inflammatory demyelination occurring in MS, recent studies indicate that B cells also play a significant role in the pathogenesis of this disease.
=== The presence of all structural varieties in the library === Formation of all structural variants that can be deduced from the BBs is an important feature of the S&P synthesis. Only the S&P method can achieve this in a single process. On the other hand, the presence of all possible structural varieties in a library assures that the library is a combinatorial one and is prepared by combinatorial synthesis.
== Developmental history == ZooMS was first published in 2009 by a team of researchers from the University of York, but the term was coined later in a publication in 2010. The original aim of ZooMS was to distinguish between sheep and goat. The bones of these two closely related species are difficult to distinguish, especially when fragmented, yet the difference between these two common domesticates is very important for our understanding of past husbandry practices. Most of the method development following the initial publication of ZooMS has focused on the extraction of collagen from the archaeological material. In the original protocol acid was used to dissolve the bone's mineral matrix and free up the collagen. In 2011 an alternative extraction method was published that used an ammonium bicarbonate buffer to solubilise the collagen without dissolving the mineral matrix. In contrast to the acid protocol, the ammonium bicarbonate protocol does not affect the size and mass of the sample, making it a much less destructive method compared to the original protocol. In fact, the ammonium bicarbonate protocol was proposed as a non-destructive protocol for ZooMS, but in practice destructive samples are still taken for this protocol (see ). Submerging a sample in ammonium bicarbonate does chemically alter the sample, which is why current practices continue to take a destructive sample.
Out-patient service In-patient services Maternity service 24 hours emergency services X-Ray, ECG Clinical Laboratory Ultrasound Facility Treatment for snake bites Immunization Ambulance service The following specialities and consultations are available:
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.